Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL).
Beer, Philip A
British journal of haematology
MetadataShow full item record
Runge, H. F., Lacy, S., Barrans, S., Beer, P. A., Painter, D., Smith, A., Roman, E., et al. (2021). Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL).. British journal of haematology, 192 (1), 216-220. https://doi.org/10.1111/bjh.17132
We recently published results of targeted sequencing applied to 928 unselected cases of DLBCL registered in the Haematological Malignancy Research Network (HMRN) registry (1). Clustering allowed us to resolve five genomic subtypes. These subtypes shared considerable overlap with those proposed in two independent genomic studies(2, 3), suggesting the potential to use genetics to stratify patients by both risk and biology. In the original studies, clustering techniques were applied to sample cohorts to reveal molecular substructure, but left open the challenge of how to classify an individual patient. This was addressed by the LymphGen classification tool (4). LymphGen assigns an individual case to one of six molecular subtypes. The tool accommodates data from exome or targeted sequencing, either with or without copy number variant (CNV) data. Separate gene expression data allows classification of a seventh, MYC-driven subtype defined by a double hit (DHL) or molecular high-grade (MHG) gene expression signature(5-7).
Humans, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone, Antineoplastic Combined Chemotherapy Protocols, Prognosis, Cluster Analysis, Mutation, Lymphoma, Large B-Cell, Diffuse, Transcriptome, Rituximab, Progression-Free Survival
HR was funded by a studentship from the Medical Research Council. DH was supported by a Clinician Scientist Fellowship from the Medical Research Council (MR/M008584/1). The Hodson laboratory receives core funding from Wellcome and MRC to the Wellcome-MRC Cambridge Stem Cell Institute and core funding from the CRUK Cambridge Cancer Centre. HMRN is supported by BCUK 15037 and CRUK 18362.
Medical Research Council (MR/M008584/1)
Embargo Lift Date
External DOI: https://doi.org/10.1111/bjh.17132
This record's URL: https://www.repository.cam.ac.uk/handle/1810/310098
All rights reserved